VERACYTE, INC.VCYTEarnings & Financial Report
Veracyte Inc. is a leading molecular diagnostics company that develops and commercializes proprietary genomic testing solutions for early, accurate detection of cancer and other complex diseases. Its offerings help healthcare providers make better clinical decisions to improve patient outcomes, with core operations in the U.S. and expanding global market presence across key clinical segments.
VCYT Q1 FY2026 Key Financial Metrics
Revenue
$139.1M
Gross Profit
$101.2M
Operating Profit
$22.6M
Net Profit
$28.7M
Gross Margin
72.7%
Operating Margin
16.3%
Net Margin
20.6%
YoY Growth
21.5%
EPS
$0.35
VERACYTE, INC. Q1 FY2026 Financial Summary
VERACYTE, INC. reported revenue of $139.1M (up 21.5% YoY) for Q1 FY2026, with a net profit of $28.7M (20.6% margin). Cost of goods sold was $37.9M, operating expenses totaled $78.5M.
Key Financial Metrics
| Total Revenue | $139.1M |
|---|---|
| Net Profit | $28.7M |
| Gross Margin | 72.7% |
| Operating Margin | 16.3% |
| Report Period | Q1 FY2026 |
Revenue Breakdown
VERACYTE, INC. Q1 FY2026 revenue of $139.1M breaks down across 3 segments, led by Testing revenue at $135.1M (97.1% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Testing revenue | $135.1M | 97.1% |
| Product revenue | $3.7M | 2.6% |
| Biopharmaceutical and other revenue | $301.0K | 0.2% |
VERACYTE, INC. Annual Revenue by Year
VERACYTE, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $517.1M).
VERACYTE, INC. Quarterly Revenue & Net Profit History
VERACYTE, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $139.1M | +21.5% | $28.7M | 20.6% |
| Q4 FY2025 | $140.6M | +18.5% | $41.1M | 29.3% |
| Q3 FY2025 | $131.9M | +13.8% | $19.1M | 14.5% |
| Q2 FY2025 | $130.2M | +13.8% | $-980.0K | -0.8% |
| Q1 FY2025 | $114.5M | +18.2% | $7.0M | 6.2% |
| Q4 FY2024 | $118.6M | +20.8% | $5.1M | 4.3% |
| Q3 FY2024 | $115.9M | +28.6% | $15.2M | 13.1% |
| Q2 FY2024 | $114.4M | +26.7% | $5.7M | 5.0% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $114.4M | $115.9M | $118.6M | $114.5M | $130.2M | $131.9M | $140.6M | $139.1M |
| YoY Growth | 26.7% | 28.6% | 20.8% | 18.2% | 13.8% | 13.8% | 18.5% | 21.5% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.23B | $1.28B | $1.30B | $1.32B | $1.34B | $1.37B | $1.41B | $1.44B |
| Liabilities | $101.8M | $99.0M | $124.1M | $120.5M | $123.0M | $110.1M | $96.4M | $92.0M |
| Equity | $1.13B | $1.18B | $1.18B | $1.19B | $1.22B | $1.26B | $1.31B | $1.34B |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $29.6M | $30.0M | $24.5M | $5.4M | $33.6M | $44.8M | $52.6M | $35.2M |